Overview
- Dr Reddy’s reported Rs 221.3 crore profit for the March quarter, down 86% year on year, as revenue fell to Rs 7,546.4 crore and North America sales dropped 51% to Rs 1,756.2 crore.
- Executives blamed the decline on weaker lenalidomide sales in the U.S., with a one‑time shelf‑stock adjustment of about Rs 450 crore and impairments further reducing profit.
- For the full year, revenue rose roughly 3% to about Rs 33,600 crore while profit fell, and the board recommended a final dividend of Rs 8 per share subject to approval.
- To reset growth, the company launched generic semaglutide injection in India under the Obeda brand, secured approval to market semaglutide tablets, and had the FDA accept its IV abatacept biosimilar for review.
- The business mix is tilting toward India and Europe, where sales grew on new launches and a nicotine‑replacement acquisition in Europe, as R&D spending fell 12% after it ended select CAR‑T programs.